Cryoablation Combined With Tirelizumab and Bevacizumab in Liver Metastatic TNBC Patients Failed by Multiline Therapy

Inclusion Criteria: * Histologically or Imageologically confirmed liver metastatic tnbc patients; * Histologically confirmed diagnosis of TNBC characterized by estrogen receptor negative (ER-), progesterone receptor negative (PR-) and human epidermal growth factor-2 receptor negative (HER2-); * ≥ 2 prior lines systemic therapy; * Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); * The patients show no signs of bile duct obstruction, and the bilirubin is below the upper limit of 1.5x normal value (ULN); * Age ≥ 18 years on the day of signing the ICF (or the legal age of consent in the jurisdiction in which the study is taking place); * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; * The functions of the patient's organs and blood system meet the requirements; * Blood system function: absolute neutrophil count (ANC) ≥ 1.5 x 109 / L, platelet count ≥ 100 x 109 / L * Renal function: estimated glomerular filtration rate or creatinine clearance \> 50 ml / min / 1.73 M2 * Liver function: total bilirubin ≤ 1.5 x ULN, AST and alt ≤ 5 x ULN * Estimated survival time ≥12 weeks. Exclusion Criteria: * The patient is currently receiving or has received irradiation or local treatment for the target lesion in the past 3 weeks. * The patient had previously received cryoablation. * The patient received major surgery within 14 days before enrolling in the study. * Palliative radiotherapy must be completed at least 2 weeks before enrolling in the study, and there is no plan for additional radiotherapy for the same lesion; ·Patients whose AE caused by radiotherapy did not recover to ≤ CTCAE 1 degree * The patient had metastatic brain lesions, including asymptomatic and well controlled lesions. * Complicated with infection and requiring intravenous antibiotic treatment. * The patient has any clinically significant disease or history that the investigator believes may endanger the safety of the patient or the reliability of the study results. * The patient has a history of any other malignancy unless the remission period exceeds 1 year. (do not exclude skin cancer, cervical cancer in situ, superficial bladder cancer, and breast cancer in radical treatment). * Female patients are pregnant or breastfeeding. * The patient received any trial drug within 14 days before receiving the first study drug. * The patient had undiminished or unstable severe toxicity (≥ CTCAE 4.0 grade 2) after previous use of another trial drug and / or previous cancer treatment, except anemia, weakness and hair loss. * Patients are allergic to the test drug or any of its excipients. * Patients are known to be HIV positive, have HCB, or have HBV infection and HBV DNA exceeds 2000 IU / ml. * The patient has a known history of drug addiction in the past 1 year, because this situation may lead to a high risk of non-compliance of the trial drug. * The patient has known active or suspected autoimmune disease. Subjects who are in a stable state and do not need systemic immunosuppressive therapy are allowed to be enrolled. * Subjects requiring systemic treatment with corticosteroids (\> 10mg / day prednisone efficacy dose) or other immunosuppressants within 14 days before the administration of the study drug were allowed to inhale or locally use steroids and adrenal hormone replacement with a dose \> 10mg / day prednisone efficacy dose in the absence of active autoimmune diseases. * The patient had a baseline corrected QT interval QTc \> 450 ms, or the patient had known QT prolongation syndrome, torsade de pointe ventricular tachycardia, symptomatic ventricular tachycardia, unstable heart syndrome within 3 months before the screening visit, \> grade 2 New York Heart Association heart failure, \> grade 2 Canadian Cardiovascular Association angina pectoris.